Skip to main content
Top
Published in: General Thoracic and Cardiovascular Surgery 10/2019

01-10-2019 | NSCLC | Original Article

Lymphatic invasion is a cause of local recurrence after wedge resection of primary lung cancer

Authors: Natsumi Matsuura, Tetsuhiko Go, Atsushi Fujiwara, Takayuki Nakano, Nariyasu Nakashima, Shintaro Tarumi, Sung Soo Chang, Hiroyasu Yokomise

Published in: General Thoracic and Cardiovascular Surgery | Issue 10/2019

Login to get access

Abstract

Objective

After securing a sufficient surgical margin at wedge resection and finding no pathologic evidence of residual tumor at the surgical margin, a considerable number of patients develop local recurrence. We investigated the correlation between sub-pleural lymphatic flow and local recurrence.

Methods

We retrospectively reviewed the medical records of 144 non-small cell lung cancer patients who underwent wedge resection between January 2006 and December 2014 at our institution.

Results

Postoperative recurrence was observed in 36 patients (25%). Of these, local recurrence was observed in 29 patients (80.5%). The proportion of all recurrence and local recurrence were significantly higher among patients with lymphatic vessel invasion (LVI) (p < 0.0001). Recurrence-free survival rate was significantly lower in patients with LVI (24.8%) than in patients without LVI (80.2%, p < 0.0001). Multivariate logistic regression analysis demonstrated LVI (odds ratio = 6.420, p = 0.0009) as a significant predictor of local recurrence.

Conclusions

Intratumoral lymphatic invasion represents a major cause of local recurrence. Although we should aim for radical surgery whenever possible, when limited surgery is the only option, postoperative adjuvant treatment may need to be considered for patients showing lymphatic invasion even at an early stage.
Literature
1.
go back to reference Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Goup. Ann Thorac Surg. 1995;60(3):615–22.CrossRefPubMed Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Goup. Ann Thorac Surg. 1995;60(3):615–22.CrossRefPubMed
2.
go back to reference Topol M, Maslon A. The problem of direct lymph drainage of the bronchopulmonary segments into the mediastinal and hilar lymph nodes. Clininal Anatomy. 2009;22:509–16.CrossRef Topol M, Maslon A. The problem of direct lymph drainage of the bronchopulmonary segments into the mediastinal and hilar lymph nodes. Clininal Anatomy. 2009;22:509–16.CrossRef
3.
go back to reference Takeda A, Nagata T, Aoki M, Umehara T, Suzuki S, Kamimura G, et al. Detection of alternative subpleural lymph flow pathways using indocyanine green fluorescence. Surg Today. 2018;48:640–8.CrossRefPubMed Takeda A, Nagata T, Aoki M, Umehara T, Suzuki S, Kamimura G, et al. Detection of alternative subpleural lymph flow pathways using indocyanine green fluorescence. Surg Today. 2018;48:640–8.CrossRefPubMed
4.
go back to reference Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3(1):46–52.CrossRefPubMed Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3(1):46–52.CrossRefPubMed
5.
go back to reference Birim O, Kappetein AP, Takkenberg JJ, van Klaveren RJ, Bogers AJ. Survival after pathological stage IA non-small cell lung cancer: tumor size matters. Ann Thorac Surg. 2005;79:1137–41.CrossRefPubMed Birim O, Kappetein AP, Takkenberg JJ, van Klaveren RJ, Bogers AJ. Survival after pathological stage IA non-small cell lung cancer: tumor size matters. Ann Thorac Surg. 2005;79:1137–41.CrossRefPubMed
6.
go back to reference Matsunaga H, Nakahara R, Igarashi S, Ishikawa Y, Suzuki H, Miyazawa N, et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008;135:44–9.CrossRef Matsunaga H, Nakahara R, Igarashi S, Ishikawa Y, Suzuki H, Miyazawa N, et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008;135:44–9.CrossRef
7.
go back to reference Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, et al. Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341–48.CrossRefPubMed Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, et al. Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341–48.CrossRefPubMed
8.
go back to reference Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, Mossetti C. et la. Significance of the presence of microscopic vascular invasion after complete resection of stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-size categories. Did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol. 2011;6:319–26.CrossRefPubMed Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, Mossetti C. et la. Significance of the presence of microscopic vascular invasion after complete resection of stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-size categories. Did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol. 2011;6:319–26.CrossRefPubMed
9.
go back to reference Harada M, Hato T, Horio H. Intratumoral lymphatic vessel involvement is an invasive indicator of completely resected pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2011;6:48–54.CrossRefPubMed Harada M, Hato T, Horio H. Intratumoral lymphatic vessel involvement is an invasive indicator of completely resected pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2011;6:48–54.CrossRefPubMed
10.
go back to reference Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M, et al. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. J Thorac Oncol. 2012;7:1263–70.CrossRefPubMed Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M, et al. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. J Thorac Oncol. 2012;7:1263–70.CrossRefPubMed
11.
go back to reference Igai H, Matsuura N, Tarumi S, Chang SS, Misaki N, Ishikawa S, et al. Prognostic factors in patients after lobectomy for p-T1aN0M0 adenocarcinoma. Eur J Cardiothorac Surg. 2012;41:603–6.CrossRefPubMed Igai H, Matsuura N, Tarumi S, Chang SS, Misaki N, Ishikawa S, et al. Prognostic factors in patients after lobectomy for p-T1aN0M0 adenocarcinoma. Eur J Cardiothorac Surg. 2012;41:603–6.CrossRefPubMed
12.
go back to reference Douillard JY, Rossel R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Naverbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7:719–27.CrossRefPubMed Douillard JY, Rossel R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Naverbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7:719–27.CrossRefPubMed
13.
go back to reference Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60.CrossRefPubMed Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60.CrossRefPubMed
14.
go back to reference Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trila of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–21.CrossRefPubMed Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trila of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–21.CrossRefPubMed
15.
go back to reference Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephan RJ, et al. A pooled analysis by LACE Collaborative Group. L Clin Oncol. 2008;26:3552–9. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephan RJ, et al. A pooled analysis by LACE Collaborative Group. L Clin Oncol. 2008;26:3552–9.
Metadata
Title
Lymphatic invasion is a cause of local recurrence after wedge resection of primary lung cancer
Authors
Natsumi Matsuura
Tetsuhiko Go
Atsushi Fujiwara
Takayuki Nakano
Nariyasu Nakashima
Shintaro Tarumi
Sung Soo Chang
Hiroyasu Yokomise
Publication date
01-10-2019
Publisher
Springer Singapore
Published in
General Thoracic and Cardiovascular Surgery / Issue 10/2019
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-019-01095-6

Other articles of this Issue 10/2019

General Thoracic and Cardiovascular Surgery 10/2019 Go to the issue